"Anosmia" the mysterious collateral damage of COVID-19

J Neurovirol. 2022 Apr;28(2):189-200. doi: 10.1007/s13365-022-01060-9. Epub 2022 Mar 5.

Abstract

COVID-19 pandemic spreads worldwide, with more than 100 million positive cases and more than 2 million deaths. From the beginning of the COVID-19 pandemic, several otolaryngologists described many cases of a sudden loss of smell (anosmia) associated with the disease with or without additional symptoms. Anosmia is often the first and sometimes the only sign in the asymptomatic carriers of COVID-19. Still, this disorder is underestimated, and it is not life-threatening. However, it significantly decreases the quality of life. This olfactory dysfunction continues in several cases even after the nasopharyngeal swab was negative. The occurrence of anosmia can be used as a screening tool for COVID-19 patients and can be used to identify these patients to accomplish the isolation and tracking procedures. In this review, we highlighted the possible mechanisms of anosmia in COVID-19 patients, major pathologies and features of anosmia, implications of anosmia in early diagnosis of COVID-19, evaluation of the smell function during COVID-19, and management and treatment options of COVID-19 anosmia.

Keywords: Anosmia; COVID-19; Diagnosis; Features; Implications; Mechanisms.

Publication types

  • Review

MeSH terms

  • Anosmia / diagnosis
  • COVID-19* / complications
  • Humans
  • Olfaction Disorders* / epidemiology
  • Pandemics
  • Quality of Life
  • SARS-CoV-2